Review Article
The Cutting Edge of Gastroenteritis
Advances in Understanding of Enteric Infection
Dalia Arostegui,
Thomas Wallach,
Dalia Arostegui
SUNY Downstate, Department of Pediatrics, Division of Pediatric Gastroenterology, Brooklyn, NY
Search for more papers by this authorCorresponding Author
Thomas Wallach
SUNY Downstate, Department of Pediatrics, Division of Pediatric Gastroenterology, Brooklyn, NY
Address correspondence and reprint requests to Thomas Wallach, MD, 450 Clarkson Ave, MSC 49, Brooklyn, NY 11203 (e-mail: [email protected]).Search for more papers by this authorDalia Arostegui,
Thomas Wallach,
Dalia Arostegui
SUNY Downstate, Department of Pediatrics, Division of Pediatric Gastroenterology, Brooklyn, NY
Search for more papers by this authorCorresponding Author
Thomas Wallach
SUNY Downstate, Department of Pediatrics, Division of Pediatric Gastroenterology, Brooklyn, NY
Address correspondence and reprint requests to Thomas Wallach, MD, 450 Clarkson Ave, MSC 49, Brooklyn, NY 11203 (e-mail: [email protected]).Search for more papers by this authorSources of Funding: No relevant grants or industry support.
The authors report no conflicts of interest.
ABSTRACT
In recent years, multiple advances have been made in the care, diagnosis, and mechanistic understanding of acute gastroenteritis (AGE). In this review, we discuss the current state of the art of diagnosis and management, as well as how changes in practice can improve care and decrease costs. We will discuss present study demonstrating the effect of AGE on the microbiome and how that may be linked to secondary effects or long-term changes. We will explore the use of novel technologies to further our capacity to understand how gastrointestinal infections occur and promulgate. Finally, will discuss advances in our understanding of how gastrointestinal infections capacitate other changes such as post-viral motility or other post viral intestinal dysfunction.
REFERENCES
- 1.Black R, Fontaine O, Lamberti L, et al. Drivers of the reduction in childhood diarrhea mortality 1980-2015 and interventions to eliminate preventable diarrhea deaths by 2030. J Glob Health 2019; 9: 020801.
- 2.Eberlin M, Chen M, Mueck T, et al. Racecadotril in the treatment of acute diarrhea in children: a systematic, comprehensive review and meta-analysis of randomized controlled trials. BMC Pediatr 2018; 18: 124.
- 3.Karve S, Krishnarajah G, Korsnes JS, et al. Burden of acute gastroenteritis, norovirus and rotavirus in a managed care population. Hum Vaccin Immunother 2014; 10: 1544–1556.
- 4.Guarino A, Ashkenazi S, Gendrel D, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases Evidence-Based Guidelines for the Management of Acute Gastroenteritis in Children in Europe: update 2014. J Pediatr Gastroenterol Nutr 2014; 59: 132–152.
- 5.Payne DC, Vinjé J, Szilagyi PG, et al. Norovirus and medically attended gastroenteritis in U. S. children. N Engl J Med 2013; 368: 1121–1130.
- 6.Hemming M, Räsänen S, Huhti L, et al. Major reduction of rotavirus, but not norovirus, gastroenteritis in children seen in hospital after the introduction of RotaTeq vaccine into the National Immunization Programme in Finland. Eur J Pediatr 2013; 172: 739–746.
- 7.Lorrot M, Bon F, El Hajje MJ, et al. Epidemiology and clinical features of gastroenteritis in hospitalised children: prospective survey during a 2-year period in a Parisian hospital, France. Eur J Clin Microbiol Infect Dis 2011; 30: 361–368.
- 8.Liu J, Platts-Mills JA, Juma J, et al. Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control study. Lancet 2016; 388: 1291–1301.
- 9.Wiegering V, Kaiser J, Tappe D, et al. Gastroenteritis in childhood: a retrospective study of 650 hospitalized pediatric patients. Int J Infect Dis 2011; 15: e401–e407.
- 10.Lo Vecchio A, Zacur GM. Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options. Curr Opin Gastroenterol 2012; 28: 1–9.
- 11.Nylund CM, Goudie A, Garza JM, et al. Clostridium difficile infection in hospitalized children in the United States. Arch Pediatr Adolesc Med 2011; 165: 451–457.
- 12.Pascarella F, Martinelli M, Miele E, et al. Impact of Clostridium difficile infection on pediatric inflammatory bowel disease. J Pediatr 2009; 154: 854–858.
- 13.Zolotor AJ, Randolph GD, Johnson JK, et al. Effectiveness of a practice-based, multimodal quality improvement intervention for gastroenteritis within a Medicaid managed care network. Pediatrics 2007; 120: e644–e650.
- 14.Hidayat S, Srie Enggar KD, Pardede N, et al. Nasogastric drip rehydration therapy in acute diarrhea with severe dehydration. Paediatr Indones 1988; 28: 79–84.
- 15.Sharifi J, Ghavami F, Nowrouzi Z, et al. Oral versus intravenous rehydration therapy in severe gastroenteritis. Arch Dis Child 1985; 60: 856–860.
- 16.Gregorio GV, Dans LF, Silvestre MA. Early versus delayed refeeding for children with acute diarrhoea. Cochrane Database Syst Rev 2011; 2011: Cd007296.
- 17.Bhatnagar S, Bahl R, Sharma PK, et al. Zinc with oral rehydration therapy reduces stool output and duration of diarrhea in hospitalized children: a randomized controlled trial. J Pediatr Gastroenterol Nutr 2004; 38: 34–40.
- 18.Goldman RD. Zinc supplementation for acute gastroenteritis. Can Fam Physician 2013; 59: 363–364.
- 19.Szajewska H, Guarino A, Hojsak I, et al. Use of probiotics for the management of acute gastroenteritis in children: an update. J Pediatr Gastroenterol Nutr 2020; 71: 261–269.
- 20.Allen SJ, Martinez EG, Gregorio GV, et al. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev 2010; 2010: Cd003048.
- 21.Gupta VK, Paul S, Dutta C. Geography, ethnicity or subsistence-specific variations in human microbiome composition and diversity. Front Microbiol 2017; 8: 1162.
- 22.Benary D, Lozano JM, Higley R, et al. Ondansetron prescription is associated with reduced return visits to the pediatric emergency department for children with gastroenteritis. Ann Emerg Med 2020; 76: 625–634.
- 23.Krammes SK, Jacobs T, Clark JM, et al. Effect of intravenous ondansetron on the QT interval of patients’ electrocardiograms. Pediatr Emerg Care 2018; 34: 38–41.
- 24.Hoffman RJ, Alansari K. Effect of intravenous ondansetron on QTc interval in children with gastroenteritis. Am J Emerg Med 2018; 36: 754–757.
- 25.Sturm JJ, Hirsh DA, Schweickert A, et al. Ondansetron use in the pediatric emergency department and effects on hospitalization and return rates: are we masking alternative diagnoses? Ann Emerg Med 2010; 55: 415–422.
- 26.Tomasik E, Ziółkowska E, Kołodziej M, et al. Systematic review with meta-analysis: ondansetron for vomiting in children with acute gastroenteritis. Aliment Pharmacol Ther 2016; 44: 438–446.
- 27.Olm M, Gonzalez FJ, Garcia-Valdecasas JC, et al. Necrotising colitis with perforation in diarrhoic patients treated with loperamide. Eur J Clin Pharmacol 1991; 40: 415–416.
- 28.Fischbach W, Andresen V, Eberlin M, et al. A comprehensive comparison of the efficacy and tolerability of racecadotril with other treatments of acute diarrhea in adults. Front Med (Lausanne) 2016; 3: 44.
- 29.Guarino A, Vecchio AL, Pirozzi MR. Clinical role of diosmectite in the management of diarrhea. Expert Opin Drug Metab Toxicol 2009; 5: 433–440.
- 30.Gao JJ, Tan M, Pohlmann PR, et al. HALT-D: a phase II evaluation of crofelemer for the prevention and prophylaxis of diarrhea in patients with breast cancer on pertuzumab-based regimens. Clin Breast Cancer 2017; 17: 76–78.
- 31.Golin-Bisello F, Bradbury N, Ameen N. STa and cGMP stimulate CFTR translocation to the surface of villus enterocytes in rat jejunum and is regulated by protein kinase G. Am J Physiol Cell Physiol 2005; 289: C708–C716.
- 32.Zachos NC, van Rossum DB, Murtazina R, et al. 4A peptide mimicking the NHE3 C-terminus stimulates basal and blocks Ca2+ and cAMP inhibition of NHE3 activity, and prevents cholera toxin-induced mouse jejunal fluid accumulation: potential role as drug therapy for diarrhea. Gastroenterology 2012; 142: S–1.
- 33.Lexmond WS, Rufo PA, Fiebiger E, et al. Electrophysiological studies into the safety of the anti-diarrheal drug clotrimazole during oral rehydration therapy. PLoS Negl Trop Dis 2015; 9: e0004098.
- 34.Jiang Y, Yu B, Yang H, et al. Shikonin inhibits intestinal calcium-activated chloride channels and prevents rotaviral diarrhea. Front Pharmacol 2016; 7: 270.
- 35.Beal SG, Tremblay EE, Toffel S, et al. A gastrointestinal PCR panel improves clinical management and lowers health care costs. J Clin Microbiol 2018; 56: e01457–17.
- 36.Kwack WG, Lim YJ, Kwon KH, et al. Outcomes and clinical relevance of stool multiplex bacterial polymerase chain reaction in patients with acute diarrhea: single center experience. Korean J Intern Med 2020; 35: 300–309.
- 37.Keske Ş, Zabun B, Aksoy K, et al. Rapid molecular detection of gastrointestinal pathogens and its role in antimicrobial stewardship. J Clin Microbiol 2018; 56: e00148–18.
- 38.Pouletty M, De Pontual L, Lopez M, et al. Multiplex PCR reveals a high prevalence of multiple pathogens in traveller's diarrhoea in children. Arch Dis Child 2019; 104: 141–146.
- 39.Goldenberg SD, Bacelar M, Brazier P, et al. A cost benefit analysis of the Luminex xTAG Gastrointestinal Pathogen Panel for detection of infectious gastroenteritis in hospitalised patients. J Infect 2015; 70: 504–511.
- 40.Nelson AM, Walk ST, Taube S, et al. Disruption of the human gut microbiota following Norovirus infection. PLoS One 2012; 7: e48224.
- 41.Chen SY, Tsai CN, Lee YS, et al. Intestinal microbiome in children with severe and complicated acute viral gastroenteritis. Sci Rep 2017; 7: 46130.
- 42.Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature 2011; 473: 174–180.
- 43.Castaño-Rodríguez N, Underwood AP, Merif J, et al. Gut microbiome analysis identifies potential etiological factors in acute gastroenteritis. Infect Immun 2018; 86: e00060–18.
- 44.Haddad EN, Sugino KY, Tucker RM, et al. Gut enterotypes are stable during Bifidobacterium and Lactobacillus probiotic supplementation. J Food Sci 2020; 85: 1596–1604.
- 45.Zhang H, Kang Z, Gong H, et al. Digestive system is a potential route of COVID-19: an analysis of single-cell coexpression pattern of key proteins in viral entry process. Gut 2020; 69: 1010–1018.
- 46.Matheis F, Muller PA, Graves CL, et al. Adrenergic signaling in muscularis macrophages limits infection-induced neuronal loss. Cell 2020; 180: 64.e16–78.e16.
- 47.Balemans D, Mondelaers SU, Cibert-Goton V, et al. Evidence for long-term sensitization of the bowel in patients with post-infectious-IBS. Sci Rep 2017; 7: 13606.
- 48.Muller PA, Koscsó B, Rajani GM, et al. Crosstalk between muscularis macrophages and enteric neurons regulates gastrointestinal motility. Cell 2014; 158: 300–313.
- 49.Sato T, Clevers H. Growing self-organizing mini-guts from a single intestinal stem cell: mechanism and applications. Science 2013; 340: 1190–1194.
- 50.Engevik MA, Engevik KA, Yacyshyn MB, et al. Human Clostridium difficile infection: inhibition of NHE3 and microbiota profile. Am J Physiol Gastrointest Liver Physiol 2015; 308: G497–509.
- 51.Hayashi H, Szászi K, Coady-Osberg N, et al. Inhibition and redistribution of NHE3, the apical Na+/H+ exchanger, by Clostridium difficile toxin B. J Gen Physiol 2004; 123: 491–504.
- 52.Engevik MA, Danhof HA, Chang-Graham AL, et al. Human intestinal enteroids as a model of Clostridioides difficile-induced enteritis. Am J Physiol-Gastrointest Liver Physiol 2020; 318: G870–G888.
- 53.Zhang YG, Wu S, Xia Y, et al. Salmonella-infected crypt-derived intestinal organoid culture system for host-bacterial interactions. Physiol Rep 2014; 2: e12147.
- 54.Karin M, Cao Y, Greten FR, et al. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002; 2: 301–310.
- 55.Greten FR, Arkan MC, Bollrath J, et al. NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell 2007; 130: 918–931.
- 56.Foulke-Abel J, In J, Yin J, et al. Human enteroids as a model of upper small intestinal ion transport physiology and pathophysiology. Gastroenterology 2016; 150: 638.e8–649.e8.
- 57.Costantini V, Morantz EK, Browne H, et al. Human norovirus replication in human intestinal enteroids as model to evaluate virus inactivation. Emerg Infect Dis 2018; 24: 1453–1464.
Citing Literature
